CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
39.24
+0.31 (0.80%)
Nov 20, 2026, 2:38 PM EST - Market open
CRISPR Therapeutics AG Stock Forecast
Stock Price Forecast
According to 23 analysts polled by S&P Global, CRISPR Therapeutics AG stock has a consensus rating of "Buy" and an average price target of $85.42. The average 1-year stock price forecast is 117.69% higher than the current stock price, while the lowest is $44 (+12.13%) and the highest is $291 (+641.59%).
Price Target: $85.42 (+117.69%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for CRISPR Therapeutics AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 9 | 8 | 8 | 9 | 9 |
| Buy | 5 | 4 | 5 | 5 | 4 | 4 |
| Hold | 10 | 9 | 9 | 9 | 10 | 10 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 25 | 22 | 22 | 22 | 23 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $80 | Buy | Reiterates | $80 | +103.87% | Nov 16, 2026 |
| UBS | UBS | Hold Maintains $52 | Hold | Maintains | $52 | +32.52% | Nov 10, 2026 |
| Needham | Needham | Buy Maintains $82 | Buy | Maintains | $82 | +108.97% | Nov 9, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $67 | Buy | Maintains | $67 | +70.74% | Nov 9, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $110 | Buy | Reiterates | $110 | +180.33% | Nov 9, 2026 |
Financial Forecast
Revenue This Year
35.49M
from 3.51M
Increased by 910.97%
Revenue Next Year
134.07M
from 35.49M
Increased by 277.83%
EPS This Year
-4.53
from -6.47
EPS Next Year
-3.67
from -4.53
EPS and Forward PE are based on non-GAAP adjusted numbers.